Management approach to psychosis in pregnancy,
Reading File
Finding Sources
Finding Sources
Searching PubMed
"psychosis" AND "pregnancy" AND "management"
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading Article
I now have comprehensive information to write a thorough, well-structured answer. Let me compile it:
Management of Psychosis in Pregnancy
Psychosis in pregnancy is a high-stakes clinical situation requiring careful balancing of maternal psychiatric stability against fetal safety. The key principle is that untreated psychosis carries greater risks to both mother and fetus than do the medications used to treat it.
Epidemiology and Risk
- Postpartum psychosis occurs in 0.1-0.25% of the general population (1-2 psychiatric hospitalisations per 1000 births)
- Pregnancy does not protect against psychotic relapse; psychosis during pregnancy predicts postpartum psychosis
- Women with bipolar disorder: ~1 in 5 experience postpartum psychotic relapse
- Women with a personal or family history of postpartum psychosis, bipolar type 1, or schizoaffective disorder: risk of postpartum psychosis can be as high as 50%
- Discontinuation of antipsychotic medication is an independent risk factor for relapse
Untreated illness risks include: harm to the mother, neglect or infanticide of the infant, poor obstetric outcomes, and impaired fetal neurodevelopment from stress, poor self-care, substance misuse, and non-attendance at antenatal care.
Preconception Counselling
- Women on antipsychotics who plan a pregnancy should be counselled as early as possible
- Drug-induced hyperprolactinaemia (common with FGAs and risperidone) can impair fertility - consider switching to a prolactin-sparing agent if pregnancy is planned
- Optimise smoking cessation, alcohol reduction, and substance use services before conception
- Discuss risks of relapse, teratogenicity, and neonatal effects in the context of untreated illness
General Principles of Medication Management
| Principle | Detail |
|---|---|
| Do not stop if stable | If a woman is stable on an antipsychotic and likely to relapse without it, advise continuation |
| Do not switch without strong reason | Switching medication risks relapse; the known drug profile is preferable |
| Use the most effective drug | Use whichever drug has worked best for the individual patient; this minimises fetal exposure by reducing the need for higher doses or polypharmacy |
| Lowest effective dose | Use the minimum dose that maintains stability |
| Monotherapy preferred | Avoid polypharmacy wherever possible |
| Regular monitoring | Plasma levels, gestational diabetes screening, fetal growth scans |
First-Generation Antipsychotics (FGAs)
FGAs (e.g. haloperidol, chlorpromazine) are unlikely to be major teratogens. Key safety data:
- A study of >1 million women found no meaningful increase in major or cardiac malformations in 733 women on FGAs
- A 2023 study of ~6.5 million women confirmed antipsychotics are not major teratogens; a possible cardiac malformation signal was noted for chlorprothixene (a rarely used agent)
- Haloperidol has a possible association with limb defects in older case reports, but this has not been confirmed in large studies and absolute risk is very low
Obstetric/neonatal concerns with FGAs:
- Gestational diabetes (increased risk)
- Preterm birth and low birth weight (more common than with SGAs)
- Neonatal somnolence and jitteriness (in ~20% of neonates exposed in the last week of gestation)
- Neonatal dyskinesia
- Neonatal jaundice (phenothiazines)
- Neonatal withdrawal symptoms, neurological disorders, and persistent pulmonary hypertension (PPHN) - absolute risk low, effects mostly mild and transient
- Higher placenta-to-birth-weight ratio and higher postpartum bleeding risk in vaginal delivery
Second-Generation Antipsychotics (SGAs)
SGAs are also unlikely to be major teratogens, supported by very large datasets:
- 9258 women on SGAs in one large US study: no meaningful increase in major/cardiac malformations
- A 2023 multinational study of 21,751 SGA-exposed pregnancies confirmed no major teratogenic effect; safety signals noted for olanzapine (oral clefts) and brain anomalies with all SGAs - these require further study but should not change prescribing decisions
Agent-specific considerations:
| Drug | Key Issues |
|---|---|
| Olanzapine | Gestational diabetes (significant risk), macrosomia, large head circumference, lower birth weight, increased ICU admissions |
| Clozapine | Continue if clinically required; theoretical risk of neonatal agranulocytosis (monitor); neonatal seizures may be slightly more common; monitor plasma levels (especially with smoking habit changes); lower adaptive behaviour scores in exposed infants vs. other SGAs in one study |
| Quetiapine | Low placental passage; increased postpartum bleeding and prolonged neonatal stay reported in Finnish data; otherwise reasonable safety profile |
| Risperidone | One study noted a small absolute risk signal for malformations - interpret with caution |
| Aripiprazole | May not increase gestational diabetes risk; possible neurodevelopmental safety signal in one 2022 cohort study, requires further study |
| Lurasidone | Available data do not suggest major teratogenic risk |
| Cariprazine | Manufacturer advises against use in pregnancy (animal malformation data); probably best avoided |
Shared SGA concerns:
- Gestational diabetes (greatest with clozapine, olanzapine, quetiapine)
- Possibly preterm birth and low birth weight
- Neonatal withdrawal effects (~15% of exposed neonates)
- PPHN (absolute risk low)
- Postpartum bleeding in vaginal delivery
Neurodevelopmental Outcomes
The evidence is reassuring overall:
- Two large cohort studies found increased ADHD and ASD rates are linked to maternal mental illness, not antipsychotic exposure
- A cohort of 667,517 children showed no association between maternal antipsychotic prescription and poorer school test scores in language and mathematics
- A 2022 birth cohort study found antipsychotics not causally associated with neurodevelopmental disorders (with the exception of an aripiprazole signal requiring further study)
Specific Clinical Scenarios
1. Existing antipsychotic user who becomes pregnant
- Continue current medication if she is stable - do not switch
- Inform her of known risks and the higher risk of untreated relapse
- Switch only if there is a compelling clinical reason (e.g. markedly teratogenic drug, high metabolic risk with olanzapine/clozapine in a woman with pre-existing diabetes)
2. First presentation of psychosis in pregnancy
- Treat with an antipsychotic; choose the agent most likely to be effective (or with which she has prior experience)
- Risk-benefit discussion fully documented
- Multidisciplinary team (MDT): psychiatrist, obstetrician, midwife, community psychiatric nurse
3. Acute severe psychosis in pregnancy
- Hospitalisation (ideally a mother-and-baby unit or specialist perinatal unit)
- If rapid tranquilisation is needed: haloperidol + promethazine is a reasonable regimen; avoid lorazepam in late pregnancy if possible due to neonatal respiratory effects; seek perinatal psychiatry input
- Refer to the 2025 systematic review of managing acute behavioural disturbance in perinatal women (PMID 40528660) for guideline-level evidence
4. High-risk women (bipolar I, schizoaffective, prior postpartum psychosis)
- Prophylactic antipsychotic medication throughout pregnancy and postpartum period is strongly recommended
- Risk of postpartum episode can reach 50%; benefits of prophylaxis clearly outweigh risks
Maudsley Guidelines Box 7.2 - Core Recommendations Summary
- Planned pregnancy should be discussed with women on antipsychotics as early as possible
- Support reduction of smoking, alcohol, and illicit substance use
- If pregnant and stable - continue antipsychotic; do not switch
- Choose the agent that previously worked best for the woman
- Be aware of neonatal effects at delivery; inform paediatric/neonatal team
- Use the lowest effective dose; monotherapy if possible
- Clozapine plasma level monitoring may be beneficial during pregnancy, especially with changes in smoking
Monitoring in Pregnancy
- Fetal: Dating scan, anomaly scan (20 weeks), growth scans from 28-32 weeks (especially with olanzapine/clozapine)
- Maternal metabolic: Fasting glucose/HbA1c, blood pressure, weight (gestational diabetes screen especially with olanzapine, clozapine, quetiapine)
- Clozapine: Continued mandatory FBC monitoring; consider plasma levels
- Psychiatric: Frequent mental state assessments; birth plan discussion; postpartum relapse prevention plan
Postpartum Planning
- The postpartum period is a very high-risk time for relapse, particularly in bipolar disorder
- Continue antipsychotic medication postpartum; discuss breastfeeding risks (most antipsychotics transfer into breast milk; quetiapine and olanzapine have the lowest relative infant dose data)
- Ensure early psychiatric follow-up within 1-2 weeks of delivery
- For high-risk women (bipolar I, schizoaffective, prior postpartum psychosis): consider prophylactic lithium or antipsychotic to be started at or soon after delivery
Recent Evidence Update
The CANMAT 2024 Clinical Practice Guideline for perinatal mood, anxiety, and related disorders (PMID 39936923, Can J Psychiatry 2025) provides updated evidence-based recommendations for perinatal psychiatric management including psychosis. A 2025 systematic review specifically on managing acute behavioural disturbance in perinatal women (PMID 40528660, AUST NZ J Obstet Gynaecol 2025) represents the most current guideline-level synthesis for acute psychosis management in this population.
Sources: The Maudsley Prescribing Guidelines in Psychiatry (15th ed.), Swanson's Family Medicine Review; CANMAT 2024 Practice Guideline (PMID 39936923); Systematic review of perinatal acute behavioural disturbance (PMID 40528660)
This is a shared conversation. Sign in to Orris to start your own chat.